NEW YORK, Jan. 4, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on AERI, PFE, NVS, and SNY which can be accessed for free by signing up to www.wallstequities.com/registration. Pharmaceutical manufacturers develop prescription and over-the-counter products that are used
Shares in Irvine, California-based Aerie Pharmaceuticals Inc. rose slightly by 0.17%, ending Wednesday's trading session at $60.55. The stock recorded a trading volume of 253,712 shares. The Company's shares have gained 17.23% over the last three months and 56.26% over the past one year. The stock is trading 13.08% above its 200-day moving average. Moreover, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have a Relative Strength Index (RSI) of 49.92.
On January 02nd, 2018, Aerie Pharma announced the appointment of Julia Williams as Director of Medical Affairs, reporting to John Maltman, Ph.D., Vice President of Medical Affairs. Ms. Williams will participate in directing the strategic and operational activities of the Company's Medical Affairs organization, initially focused on the launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%. Get the full research report on AERI for free by clicking below at: www.wallstequities.com/registration/?symbol=AERI
New York headquartered Pfizer Inc.'s stock climbed slightly by 0.74%, closing the day at $36.71 with a total trading volume of 13.46 million shares. The Company's shares have advanced 0.99% in the past month, 1.58% in the previous three months, and 11.24% over the past year. The stock is trading 2.29% and 6.85% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have an RSI of 59.42.
On December 27th, 2017, Pfizer announced that Mikael Dolsten, President - Worldwide R&D, will present at the 36th Annual J.P. Morgan Healthcare Conference on January 08th, 2018, at 8:30 a.m. PST. The webcast of the presentation may be accessed on the Company's website. Access the free research report on PFE now by signing up at: www.wallstequities.com/registration/?symbol=PFE
On Wednesday, shares in Basel, Switzerland headquartered Novartis AG recorded a trading volume of 1.15 million shares. The stock ended the day 0.78% higher at $85.34. The Company's shares have advanced 2.68% since the last one week, and are trading above their 50-day and 200-day moving averages by 1.97% and 3.89%, respectively. Furthermore, shares of Novartis, which researches, develops, manufactures, and markets healthcare products worldwide, have an RSI of 59.03.
On December 06th, 2017, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Neutral' to 'Underperform'.
On December 11th, 2017, Novartis Pharmaceuticals Corporation, an affiliate of Novartis, announced that results from a post hoc subgroup analysis of the Phase-II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin monoclonal antibody, delayed the time to first sickle cell pain crisis in patients vs. placebo in key subgroups of adult patients with sickle cell disease. Findings were featured during an oral session at the 59th American Society of Hematology Annual Meeting held that day. Are you already registered with Wall St. Equities? Do so now for free, and get the report on NVS at: www.wallstequities.com/registration/?symbol=NVS
Paris, France headquartered Sanofi's stock declined 0.28%, finishing yesterday's session at $43.20 with a total trading volume of 1.12 million shares. The Company's shares have advanced 0.79% since the last week and 5.31% over the past year. The stock is trading below its 50-day moving average by 3.97%. Additionally, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have an RSI of 40.28.
On December 06th, 2017, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Buy' to 'Neutral'.
On December 18th, 2017, Sanofi Genzyme, a business unit of Sanofi, and Alnylam Pharmaceuticals, Inc., a RNAi therapeutics company, announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis. Patisiran was previously granted accelerated assessment by the EMA, potentially reducing the EMA's evaluation time from 210 to 150 days. Aspiring Member, please take a moment to register below for your free research report on SNY at: www.wallstequities.com/registration/?symbol=SNY
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-drug-makers-stocks----aerie-pharma-pfizer-novartis-and-sanofi-300577493.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All